Video

Associating Genes With Melanoma Risk

Author(s):

Maria T. Landi, M.D., Ph.D.
Conference|World Congress on Melanoma

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.

The large, meta-analysis observed 27,000 patients with melanoma and 50,000 controls from the United States, Australia and Europe and discovered 19 additional genes that showed a strong correlation with melanoma risk. Included were alterations in pigmentation pathways, telomeres, immunity and signalisn and transcription pathways.

In the future, Landi and her research team will be adding about 10,000 more patients to hopefully identify more genetic associations with melanoma.

Related Videos
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of man with grey hair.
Image of woman with blonde hair.
Related Content
Illustration of bladder.
February 21st 2025

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

Roman Fabbricatore
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of bladder cancer.
February 20th 2025

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Jax DiEugenio
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
Top Cancer Headlines from 2023
January 2nd 2024

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
In patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses. © stock.adobe.com.
February 18th 2025

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

Ashling Wahner
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Illustration of bladder.
February 18th 2025

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

Kristi Rosa
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.